Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Toekomstige innovaties in nieuwe detectie voor atriumfibrilleren (FIND-AF): pilotstudie (FIND-AF)

30 september 2026 bijgewerkt door: Prof Christopher Gale, University of Leeds

Toekomstige innovaties in nieuwe detectie van atriumfibrilleren (FIND-AF): pilotstudie van een risicoscore voor vroege detectie van atriumfibrilleren

The purpose of this study is to trial a new intervention - risk-guided AF screening using an EHR-based risk score and remote ECG monitoring process - and to characterise individuals at elevated predicted AF risk.

Studie Overzicht

Toestand

Actief, niet wervend

Interventie / Behandeling

Gedetailleerde beschrijving

This pilot study will use a post-market device within its intended purpose and involve a change in standard care - that is the offer of ECG monitoring for individuals at risk of AF to understand whether this leads to an increase in detection rates of AF, and follow-through prescription of oral anticoagulation.

Starting with the population that are eligible for oral anticoagulation (men with a CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3), but without AF, this pilot study will use FIND-AF within its intended purpose to predict the absolute risk of AF diagnosis for individuals within the next 6 months. It will be observed whether systematic AF screening leads to higher detection rates of AF in individuals at higher risk for AF than individuals at lower risk for AF.

This will give pilot data for whether systematic screening for AF in individuals at higher AF risk results in an incrementally higher yield of AF detection compared with screening approaches that have been targeted by age and risk of AF-related stroke. If the pilot shows that detection rates for AF are higher in the group at higher AF risk, then it would be suitable to plan a randomised controlled trial to determine whether systematic AF screening guided by AF risk increases detection rates of AF compared with routine care, and whether this is associated with a lower rate of stroke. The detection rates during systematic AF screening in this pilot study for individuals at higher and lower risk can establish power calculations required for a full-scale study and whether the numeric score at which a clinician would implement the intervention can be optimised.

In addition, this pilot study will establish the technical, logistic and administrative feasibility of a full-scale remote AF screening study including issues of recruitment and protocol adherence. It will also inform as to whether individuals diagnosed with AF by systematic AF screening in the community will receive oral anticoagulation interventions in primary care, and thus whether treatment of screen-detected AF in a full-scale study should be implemented in primary care or in secondary care under cardiology.

Finally this study will offer participants at higher AF risk the opportunity to attend a research clinic to determine whether these individuals have risk factors and comorbidities that could be identified and treated to reduce their subsequent risk of AF and other adverse events. This will establish whether individuals at risk of AF will attend for review, and their burden of modifiable risk factors for AF. This will establish power calculations that would be required for a full-scale study to test the hypothesis that primary prevention of AF is possible through interventions aimed at individuals at risk of AF.

Studietype

Observationeel

Inschrijving (Geschat)

1955

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • West Yorkshire
      • Leeds, West Yorkshire, Verenigd Koninkrijk, LS2 9JT
        • University of Leeds

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

30 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients aged >30 will be invited to screening in primary care from information present in their electronic health record (EHR) and their FIND-AF score. They will be given Zenicor ECG devices for up to period of 3 week during which they will be asked to record 4 daily ECG recordings.

Those patients who are higher risk for AF based on their FIND-AF score, will be reviewed further for multi-modal phenotyping.

Patient with new AF detected will be managed by their primary care clinicians.

Beschrijving

Inclusion Criteria:

  • Age at enrolment ≥30 years
  • Men with CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3

Exclusion Criteria:

  • Known diagnosis of AF
  • On anticoagulation therapy
  • On the palliative care register
  • Unable to give written informed consent for participation in the study
  • Unable to adhere to the study requirements

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Tijdsspanne: 6 months

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

6 months
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Tijdsspanne: 5 years

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

5 years
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Tijdsspanne: 10 years

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

10 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Tijdsspanne: 6 months

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

6 months
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Tijdsspanne: 5 years

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

5 years
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Tijdsspanne: 10 years

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

10 years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To determine the AF detection rates amongst participants who are identified as higher risk and lower risk, including in the periods outside of ECG monitoring to determine the incremental yield that is achieved by ECG monitoring over routine care
Tijdsspanne: 6 months

Risk of recorded AF diagnosis in EHR between individuals identified at higher and lower risk at six months after enrolment

6 months
To determine how diagnostic yield, C statistic/AUROC, NPV, PPV, sensitivity and specificity, varies at different cut off points of the FIND-AF risk score
Tijdsspanne: 6 months

Diagnostic yield, PPV, NPV, sensitivity and specificity amongst participants who receive ECG monitoring, to understand whether the numeric score at which a clinician implements ECG monitoring can be optimised

6 months
To determine the C statistic/AUROC, NPV, PPV, sensitivity and specificity for alternative approaches to guide systematic AF screening in participants who receive ECG monitoring:
Tijdsspanne: 6 months

Diagnostic yield, C statistic/AUROC, PPV, NPV, sensitivity and specificity in patients who are : CHA2DS2VASC≥3 in men and CHA2DS2VASC≥4 in women, age ≥70 years and age 75 and 76 years

6 months
To determine if yield from ECG monitoring varies across age groups (≥75 years and ≤75 years) and sex (men and women)
Tijdsspanne: 6 months

AF detection rates and risks comparing higher and lower risk participants stratified by subgroup

6 months
To determine recruitment rates, overall study.
Tijdsspanne: Up to 24 months

Number (%) of people who consent to participate compared to number of people who are invited

Up to 24 months
To determine withdrawal rates
Tijdsspanne: Up to 24 months

Number (%) of people who consent to participate but subsequently withdraw consent / decline ECG monitoring

Up to 24 months
To determine if there are differences between those who participate and those that do not participate
Tijdsspanne: Up to 24 months

Characteristics of those who consent to participate and do not consent to participate

Up to 24 months
To determine if there are differences between those who participate and those that withdraw
Tijdsspanne: Up to 24 months

Characteristics of those who participate and those that withdraw

Up to 24 months
To determine the adherence of ECG recordings amongst participants
Tijdsspanne: Up to 24 months

Mean number of recordings compared to the maximum stipulated Number (%) of participants who record less than 50% of stipulated amount of ECG recordings

Up to 24 months
To determine the number of ECG recordings that need to be reviewed for possible AF detection
Tijdsspanne: Up to 24 months

Number (%) of ECG recordings flagged as abnormal by the algorithm within ECG recorder software that require manual review to assess for potential AF diagnosis

Up to 24 months
To determine the burden of other arrhythmias that are diagnosed through ECG monitoring in participants identified as higher risk and lower risk
Tijdsspanne: Up to 24 months

Number (%) of participants who are diagnosed with other arrhythmias ( (atrial tachycardia, supraventricular tachycardia, 2nd degree AV block, high grade AV block or 3rd degree heart block, pause/asystole, ventricular tachycardia, ventricular fibrillation) during ECG monitoring in participants

Up to 24 months
To determine the burden of non-diagnostic rhythm reports from ECG monitoring
Tijdsspanne: Up to 24 months

Number (%) of participants who have an ECG monitoring period with consistent poor quality which precludes a diagnostic result

Up to 24 months
To determine recruitment rates - research clinic appointment
Tijdsspanne: Up to 24 months

Number (%) of people who consent to attend a research clinic appointment compared to number of people who are invited

Up to 24 months
To determine what other conditions and cardiovascular risk factors are identified amongst participants classified as higher risk for AF at research clinic
Tijdsspanne: End of recruitment

Descriptive statistics of demographics, morbidities, medications, and cardiac ultrasound findings

End of recruitment
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Tijdsspanne: 5 years from completion of recruitment

Number (%) of participants who experience at 5 years:

  • AF
  • Ischaemic stroke
  • Haemorrhagic stroke
  • Systemic embolism
  • Gastrointestinal or intracranial bleeding
  • Death
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Heart failure
  • Diabetes mellitus
  • Myocardial infarction
  • Peripheral vascular disease
  • Valvular heart disease
5 years from completion of recruitment
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Tijdsspanne: 10 years from completion of recruitment

Number (%) of participants who experience at 10 years:

  • AF
  • Ischaemic stroke
  • Haemorrhagic stroke
  • Systemic embolism
  • Gastrointestinal or intracranial bleeding
  • Death
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Heart failure
  • Diabetes mellitus
  • Myocardial infarction
  • Peripheral vascular disease
  • Valvular heart disease
10 years from completion of recruitment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Chris Gale, Yes, University of Leeds

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 oktober 2023

Primaire voltooiing (Werkelijk)

16 juni 2025

Studie voltooiing (Geschat)

28 februari 2033

Studieregistratiedata

Eerst ingediend

18 mei 2023

Eerst ingediend dat voldeed aan de QC-criteria

31 mei 2023

Eerst geplaatst (Werkelijk)

12 juni 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

2 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

30 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

No individual participant data will be shared.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren